BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 83 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,402 | -62.0% | 1,740 | 0.0% | 0.00% | – |
| Q2 2023 | $11,588 | -64.3% | 1,740 | 0.0% | 0.00% | – |
| Q1 2023 | $32,468 | -13.1% | 1,740 | 0.0% | 0.00% | – |
| Q4 2022 | $37,375 | +834.4% | 1,740 | +411.8% | 0.00% | – |
| Q3 2022 | $4,000 | +300.0% | 340 | +1033.3% | 0.00% | – |
| Q2 2021 | $1,000 | – | 30 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 550,000 | $23,848,000 | 3.05% |
| SPHERA FUNDS MANAGEMENT LTD. | 269,300 | $11,677,000 | 1.15% |
| Avidity Partners Management LP | 538,000 | $23,328,000 | 1.08% |
| Knoll Capital Management, LLC | 20,000 | $867,000 | 0.71% |
| Maven Securities LTD | 200,000 | $8,610,000 | 0.71% |
| Prosight Management, LP | 29,800 | $1,292,000 | 0.62% |
| Artemis Investment Management LLP | 1,001,708 | $43,383,000 | 0.54% |
| Ikarian Capital, LLC | 150,000 | $6,504,000 | 0.47% |
| AlphaCentric Advisors LLC | 20,000 | $867,000 | 0.42% |
| MOODY ALDRICH PARTNERS LLC | 19,872 | $862,000 | 0.18% |